BIOLASE Inc. (NASDAQ:BIOL) has a beta of 1.85. The stock’s Relative Strength Index (RSI) is 72.76, with weekly volatility at 11.31% and ATR at 0.02. The BIOL stock’s 52-week price range has touched low of $0.21 and a $0.96 high. Its shares traded higher over the last trading session, gaining 22.86% on 12/01/20. The shares fell to a low of $0.3013 before closing at $0.37. Intraday shares traded counted 38.92 million, which was -1685.54% lower than its 30-day average trading volume of 2.18M. BIOL’s previous close was $0.30 while the outstanding shares total 93.01M.
Investors have identified the Medical Devices company BIOLASE Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $33.56 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
BIOLASE Inc. (BIOL) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For BIOL, the company has in raw cash 19.16 million on their books with 12.95 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 36047000 million total, with 21433000 million as their total liabilities.
BIOL were able to record -11.53 million as free cash flow during the third quarter of the year, this saw their quarterly net cash flow reduce by 13.06 million. In cash movements, the company had a total of -11.45 million as operating cash flow.
Potential earnings growth for BIOLASE Inc. (BIOL)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, BIOLASE Inc. recorded a total of 6.54 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with -32.22% coming in sequential stages and their sales for the third quarter increasing by 55.07%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 4.26 million trying to sell their products during the last quarter, with the result yielding a gross income of 2.27 million. This allows shareholders to hold on to 93.01M with the revenue now reading 0.00 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (-0.06 cents a share).
Having a look at the company’s valuation, the company is expected to record -0.77 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on BIOL sounds very interesting.
Is the stock of BIOL attractive?
In related news, 10% Owner, FEINBERG LARRY N sold 1,770,312 shares of the company’s stock in a transaction that recorded on Jun 09. The sale was performed at an average price of 0.55, for a total value of 976,010. As the sale deal closes, the 10% Owner, FEINBERG LARRY N now sold 3,402,938 shares of the company’s stock, valued at 1,885,908. Also, 10% Owner, SCHULER JACK W sold 1,307,931 shares of the company’s stock in a deal that was recorded on Feb 11. The shares were price at an average price of 0.60 per share, with a total market value of 784,759. In the last 6 months, insiders have changed their ownership in shares of company stock by 10.63%.